• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Hepatitis D - Pipeline Review, H2 2012 Product Image

Hepatitis D - Pipeline Review, H2 2012

  • ID: 2366292
  • December 2012
  • 47 pages
  • Global Markets Direct

Hepatitis D – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hepatitis D - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis D, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis D. Hepatitis D - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatitis D.
- A review of the Hepatitis D products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Hepatitis D Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hepatitis D 7
Hepatitis D Therapeutics under Development by Companies 9
Hepatitis D Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Hepatitis D Therapeutics – Products under Development by Companies 15
Hepatitis D Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Hepatitis D Therapeutics Development 17
F. Hoffmann-La Roche Ltd. 17
Medgenics Inc. 18
BioDiem Ltd 19
Eiger BioPharmaceuticals, Inc. 20
Hepatitis D – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
peginterferon alfa-2a - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
peg-interferon alfa-2a + tenofovir - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PEG-IFN Alfa-2a + Tenofovir - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
EBP-994 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EBP-921 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
squalamine lactate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Lonafarnib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Hepatitis D Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Myrcludex-B - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Hepatitis D Therapeutics – Drug Profile Updates 38
Hepatitis D – Product Development Milestones 39
Featured News & Press Releases 39
Jun 20, 2012: Medgenics Receives FDA Orphan Drug Designation For INFRADURE Biopump To Treat Hepatitis D 39
Apr 23, 2012: Medgenics Files For US Orphan Drug Designation For INFRADURE For Treatment Of Hepatitis D 40
Sep 19, 2011: Georgetown University Medical Center Researcher Proves Shark Compound To Be Potential Drug To Treat Human Viruses 41
Mar 31, 2011: Merck Announces Results From New Data Analyses Of VICTRELIS 42
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products Under Development for Hepatitis D, H2 2012 7
Products under Development for Hepatitis D – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
F. Hoffmann-La Roche Ltd., H2 2012 17
Medgenics Inc., H2 2012 18
BioDiem Ltd, H2 2012 19
Eiger BioPharmaceuticals, Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Hepatitis D Therapeutics – Drug Profile Updates 38

List of Figures
Number of Products under Development for Hepatitis D, H2 2012 7
Products under Development for Hepatitis D – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Discovery and Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos